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The structure of the human major histocompatability (MHC)
class I molecule HLA-A*0301 (HLA-A3) in complex with a
nonameric peptide (KLIETYFSK) has been determined by
X-ray crystallography to 2.7 A ˚ resolution. HLA-A3 is a
predisposing allele for multiple sclerosis (MS), an auto-
immune disease of the central nervous system. The KLIE-
TYFSK peptide is a naturally processed epitope of proteolipid
protein, a myelin protein and candidate target for immune-
mediated myelin destruction in MS. Comparison of the
structure of HLA-A3 with that of HLA-A2, an MHC class I
molecule which is protective against MS, indicates that both
MHC class I molecules present very similar faces for T-cell
receptor recognition whilst differing in the speciﬁcity of their
peptide-binding grooves. These characteristics may underlie
the opposing (predisposing versus protective) associations
that they exhibit both in humans and in mouse models of
MS-like disease. Furthermore, subtle alterations within the
peptide-binding groove of HLA-A3 and other A3-like MHC
class I molecules, members of the so-called A3 superfamily,
may be sufﬁcient to alter their presentation of autoantigen
peptides such as KLIETYFSK. This in turn may modulate
their contribution to the associated risk of autoimmune
disease.
Received 2 September 2010
Accepted 2 March 2011
PDB Reference: HLA-A*0301
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1. Introduction
Major histocompatability (MHC) class I molecules are
heterodimeric glycoproteins that are present on the surface of
almost all nucleated cells. Their primary role is to present
peptides derived from endogenous cellular proteins for
recognition by T-cell receptors (TCRs) on the surface of CD8
+
cytotoxic T-lymphocytes (CTLs). In this manner, MHC class I
molecules contribute to an immune surveillance system in
which TCRs monitor the population of presented peptides for
indications of cellular infection or transformation. TCR
recognition of an MHC class I molecule-presented nonself-
peptide or altered self-peptide induces CD8
+ CTL-mediated
destruction of the target cell and as such MHC class I mole-
cules are at the forefront of adaptive immune defences
(Guermonprez et al., 2002).
The ﬁrst atomic level structure of an MHC class I molecule
was reported for HLA-A2 (Bjorkman et al., 1987; Saper et al.,
1991). Subsequently, structures of various MHC class I allelic
products in complex with various speciﬁc peptides have been
reported. Each MHC class I structure has revealed an archi-
tecture fundamentally similar to that of HLA-A2. Brieﬂy, the
  chain forms two membrane-distal domains ( 1 and  2)
which together generate a solvent-exposed groove composedof an eight-antiparallel- -strand platform bordered on either
long edge by an  -helix. The membrane-proximal immuno-
globulin-like  3 domain of the   chain associates non-
covalently with the invariant immunoglobulin-like  2-
microglobulin ( 2m). Peptides (typically 8–10 amino acids in
length) bind within the groove, stabilized by a network of
conserved hydrogen-bond interactions and allele-speciﬁc
contacts. Polymorphisms in the residues lining the groove
inﬂuence the preference that each MHC groove has for
particular peptide motifs, deﬁned as preferences for particular
anchor residues whose side chains bind in speciﬁc pockets
within the groove. Individual HLA alleles have been grouped
into HLA superfamilies on the basis of commonalities in these
peptide-motif preferences (Sidney et al., 2008; Sette & Sidney,
1999).
Multiple sclerosis (MS) is an autoimmune disease of the
central nervous system that is characterized by demyelination
and neuronal and axonal degeneration. The disease arises
from an autoreactive T-cell mediated immune response
directed against healthy myelin, the lipid-protein sheath which
encases neuronal axons (reviewed by Sospedra & Martin,
2005). MS is genetically associated with the HLA region on
chromosome 6, which is consistent with a role for MHC
molecules in presentation of myelin-associated peptides to
potentially autoreactive T cells. Whilst MHC class II alleles (in
particular those of the DR2 haplotype: HLA-DRB5*0101,
HLA-DRB1*0501 and HLA-DQB1*0601) remain the
strongest identiﬁed associated genetic risk factor for MS, there
is evidence for an independent association with the MHC class
I molecule-encoding HLA-A region. More speciﬁcally, HLA-
A3 approximately doubles disease risk, whilst HLA-A2 exerts
a dominant protective effect, approximately halving the rela-
tive risk conferred by either HLA-A3 or the DR2 haplotype
(Harbo et al., 2004; Fogdell-Hahn et al., 2000).
Animal models of MS-like disease have helped to uncover
complexities in the opposing actions of HLA-A3 and HLA-
A2 in MS. Transgenic mice expressing either or both of these
MHC class I alleles were crossed with a mouse transgenic for a
MS patient-derived T-cell receptor that recognizes a peptide
from proteolipid protein (PLP residues 45–53; KLIETYFSK)
presented by HLA-A3 molecules (Honma et al., 1997);
proteolipid protein is a major component of myelin and a
candidate target for immune-mediated myelin destruction
(Sospedra & Martin, 2005). These studies showed that the
transgenic CTLs recognizing HLA-A3/PLP45-53 are sufﬁcient
to initiate an early mild form of MS-like disease, whilst co-
expression of HLA-A2 as an additional transgene signiﬁcantly
moderated disease in the same mice. This protection resulted
mainly from the deletion of most of the autoreactive CTLs in
the thymus and partly from down-regulation of surface auto-
reactive TCR expression (Friese et al., 2008).
Notably, in contrast to HLA-A3, other members of the A3
superfamily (HLA-A11, HLA-A3301, HLA-A3101 and HLA-
Aw*6801), which by deﬁnition share peptide-binding proper-
ties with HLA-A3, do not appear to be associated with MS
(Harbo et al., 2004; Kheradvar et al., 2004). A report of a
modest predisposing effect of HLA-A11 in the Indian popu-
lation was tempered by the particular small sample group
studied (Kankonkar et al., 2003). In order to address the
possible molecular determinants of the opposing disease
associations of HLA-A3 and HLA-A2 and the neutrality of
other
A3-superfamily members, we solved the crystal structure of
HLA-A3 in complex with the autoantigen peptide PLP45-53
(KLIETYFSK). This structure provides the ﬁrst experimen-
tally derived crystallographic view of the HLA-A3 peptide-
binding groove, allowing detailed comparison with previously
reported structures of other members of the A3 superfamily.
The HLA-A3/PLP45-53 structure also allows us to assess the
extent of structural equivalence between the surface exposed
for TCR recognition in HLA-A2 and in HLA-A3; a poten-
tially important contributing factor to the frequency of TCR
cross-reactivity to HLA-A2 and HLA-A3 peptide complexes.
2. Materials and methods
2.1. Cloning
cDNA of HLA-A*0301   chain was derived by reverse
transcription of mRNA isolated from an HLA-A*0301 posi-
tive donor and DNA encoding residues 1–274 was ampliﬁed
by polymerase chain reaction. The ﬁnal HLA-A*0301
sequence was inserted into the pET22b+ vector (Novagen)
and veriﬁed by sequencing.
2.2. Protein production and purification
Recombinant  2m and HLA*A301   chain were produced
as described previously (Friese et al., 2008). Brieﬂy,  2m and
HLA*A301   chain were expressed in Escherichia coli BLR
(DE3) cells (Novagen) as inclusion bodies, which were
subsequently isolated, washed in Triton X-100 and resolubi-
lized in 8 M urea, 10 mM NaH2PO4,1 0 m M Tris pH 8.0,
0.1 mM EDTA, 0.1 mM DTT. Equal amounts of  2m and
HLA*A301   chain were then refolded together with PLP45-
53 peptide (ratio 3:3:1) by rapid dilution in 100 mM Tris pH
8.0, 2 mM EDTA, 400 mM l-arginine–HCl, 5 mM reduced
glutathione, 0.5 mM oxidized glutathione for 72 h at 277 K.
Refolded MHC molecules were puriﬁed by size-exclusion
chromatography on a Superdex 75pg HiLoad 26/60 column
(GE Healthcare) in 20 mM Tris pH 8.0, 0.1 M NaCl, concen-
trated and then frozen at 193 K in aliquots. Prior to crystal-
lization, the A3–PLP45-53 complexes were further puriﬁed by
anion-exchange chromatography on a 5 ml HiTrap QFF
column (GE Healthcare) eluting with a salt gradient to 1 M
NaCl in 20 mM Tris pH 8.0. Puriﬁed protein was exchanged
into 10 mM NaCl, 10 mM HEPES pH 7.0 and concentrated to
6.9 mg ml
 1.
2.3. Peptide production and purification
The PLP45-53 (KLIETYFSK) peptide used to generate
HLA-A3 complexes was purchased from Schafner-N
(Copenhagen) as a >99% HPLC-puriﬁed preparation
synthesized using FMOC chemistry.
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Crystallization experiments were set up at 293 K using a
Cartesian Technologies Microsys Mic4000 (Walter et al., 2005)
with 100 nl protein solution (6.9 mg ml
 1 in 10 mM NaCl,
10 mM HEPES pH 7.0) and 100 nl reservoir solution. Needle-
like crystals [average dimensions of 20–30 mm (width)   230–
270 mm (length)   10–15 mm (depth)] were grown by the
sitting-drop vapour-diffusion method against a reservoir
consisting of 20%(w/v) polyethylene glycol 3350, 0.1 M Bis-
Tris propane pH 8.5 and 0.2 M sodium/potassium phosphate
(Molecular Dimensions PACT Premier condition No. 94) and
used directly for data collection. A single-crystal was cryo-
protected in 25% ethylene glycol and vitriﬁed at 100 K. A
complete data set to 2.7 A ˚ was collected at the Diamond Light
Source, Oxfordshire, England on beamline I04 (beam
diameter of 80–100 mm). The data were processed and scaled
with the HKL-2000 suite (Otwinowski & Minor, 1997). The
crystal belonged to space group P212121, with unit-cell para-
meters a = 62.9, b= 65.5, c= 107.3 A ˚ ,  =   =   =9 0  . There is
one molecule in the asymmetric unit.
2.5. Structure determination and refinement
The structure of A3–PLP45-53 was solved by molecular
replacement with MOLREP (Vagin & Teplyakov, 2010) using
the structure of HLA-A2 with the peptide omitted (PDB entry
1duz; Khan et al., 2000) as a search model. Validating the
molecular-replacement solution, the initial Fo   Fc difference
map contoured at 3  showed clear electron density along the
peptide-binding groove corresponding to the PLP45-53
peptide. Several rounds of manual inspection and rebuilding
using Coot (Emsley & Cowtan, 2004) were performed inter-
spersed by restrained reﬁnement in REFMAC5 (Murshudov et
al., 2011). This included manual building of the PLP45-53
(KLIETYFSK) peptide. The PHENIX software suite (Adams
et al., 2002) was then employed for ﬁnal rounds of individual
ADP and TLS reﬁnement. Groups for TLS were deﬁned using
the TLSMD server (Painter & Merritt, 2006). The model was
reﬁned to convergence against 95% of the data to a ﬁnal R
factor of 19% and Rfree of 25%. Full details of crystallization,
data collection, processing and reﬁnement can be found in
Table 1. The ﬁnal structure contains the HLA-A*0301   chain
residues 2–274, the  2m residues 1–98, KLIETYFSK peptide
and 34 water molecules.
2.6. Structure superposition and graphical representations
All superpositions of atomic structures were performed
using SHP (Stuart et al., 1979). All graphical representations
of atomic models were generated with PyMOL (http://
www.pymol.org).
2.7. Model quality and analysis
The ﬁnal model was validated using MolProbity (Chen et
al., 2010) and interactions between the peptide and binding
groove were analysed using LIGPLOT (Wallace et al., 1995).
3. Results and discussion
The structure of PLP45-53 in complex with HLA-A3 (A3–
PLP45-53) was determined at 2.7 A ˚ resolution to an R factor
of 19.3% (Rfree = 25%). Details of data collection and addi-
tional indicators of the quality of the model are given in
Table 1. The architecture of A3–PLP45-53 is typical of all
previous MHC class I structures (Fig. 1a) and the peptide-
binding groove can be described in terms of the six classic
MHC class I molecule pockets A–F (nomenclature as deﬁned
in Saper et al., 1991; see inset in Fig. 1b). PLP45-53, a nona-
meric peptide, adopts a typical arched conformation within
this groove with its N- and C-terminal residues bound in the A
and F pockets, respectively (Fig. 1). MHC residues implicated
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Figure 1
The crystal structure ofA3–PLP45-53. (a) The view isfrom above into the
binding groove of A3–PLP45-53. The MHC heavy chain is shown in blue
and the peptide PLP45-53 in red.  A-weighted Fo   Fc electron density
for the peptide PLP45-53 (generated in PHENIX after deletion of the
peptide followed by simulated annealing to minimize model bias) is also
shown contoured at 2.7 .( b) Characteristics of the HLA-A3 peptide-
binding groove. View from above into the binding groove of HLA-A3.
The side chains of individual MHC heavy-chain residues involved in
peptide binding are shown as sticks and labelled. The schematic inset
provides a key to the locations of the canonical pockets A–F.in binding PLP45-53 are illustrated in Fig. 1(b) and their
interactions are listed in Table 2.
3.1. Characteristics of the HLA-A3 peptide-binding groove
The canonical hydrogen-bond network between nonpoly-
morphic A-pocket residues and the main-chain atoms of the
peptide N-terminus is conserved in A3–PLP45-53 (Guo et al.,
1992; Silver et al., 1992), Additional hydrophobic interactions
between the aliphatic portion of the Lys side chain and the
ring of Trp167 further stabilize the peptide position 1 (P1) Lys
within the pocket (Table 2).
The B pocket is a primary peptide anchor-binding pocket in
HLA-A3 (Maier et al., 1994; Falk et al., 1991) alleles. The most
signiﬁcant residues inﬂuencing the character and thus peptide
side-chain binding speciﬁcity of the B pocket of HLA-A3 are
Tyr7, Phe9, Met45, Glu63, Asn66, Val67, Gln70 and Tyr99. The
pocket has a predominantly hydro-
phobic character consistent with the
reported preference for Val, Leu and
Met at position 2 of the peptides which
bind to HLA-A3 (Maier et al., 1994).
PLP P2 Leu tucks under Asn66 with its
side chain directed towards the  1 helix
and its main chain involved in a
hydrogen bond to Glu63 (Table 2).
However, it does not occupy the entire
volume available, which is consistent
with the ability of this pocket to also
accommodate a larger Met side chain.
P3 Ile sits snugly within the D pocket
with its side chain orientated parallel to
the  2 helix and its main chain involved
in a hydrogen bond to Tyr99. Hydro-
phobic interactions with Tyr159 and
Tyr99 further stabilize binding. There is
a very pronounced arch in the peptide
backbone from P3 to P4 that is typicalof
nonameric peptides bound to MHC
class I molecules (Madden et al., 1991).
As a result, both P4 Glu and P5 Thr are
solvent-exposed and extend above the
binding groove, positioning them as
potential TCR contact residues. Neither
of these peptide residues makes any
contacts to MHC heavy-chain residues
and there is insufﬁcient density to
unambiguously model the position of
the P4 Glu side chain, which is consis-
tent with some ﬂexibility (Fig. 1a). The
groove opens beneath the main-chain
atoms of P6 Tyr to form the C pocket.
Rather than dock into this available
volume, the aromatic ring of P6 Tyr is
positioned approximately parallel to the
 1 helix and directed towards the N-
terminus of the peptide, where it is
stabilized by a hydrogen bond to Asn66 and hydrophobic
interactions with residues Ala69, Thr73 and Gln70. A water
molecule occupies the remaining volume of pocket C co-
ordinated by Tyr99, Glu70 and the hydroxyl group of P6 Tyr.
In contrast to residues P4–P6, the P7 Phe side chain is deeply
buried within the groove inserting into the E pocket. The
character of this pocket is predominantly hydrophobic, with
Leu156 at its base and Trp147 contributing to its border. P7
Phe is stabilized within this pocket via hydrophobic stacking of
its aromatic ring against the alkyl stalk of the Gln152 side
chain and by additional hydrophobic interactions with Tyr147.
The hydroxyl group of P8 Ser is entirely solvent-exposed. A
main-chain hydrogen bond to Trp147 and an additional side-
chain hydrogen bond to Lys146 help to stabilize this residue
within the groove.
The F pocket of HLA-A3 is identical to that of HLA-A11,
which shares all of the same polymorphic residues at the
research papers
450 McMahon et al.   HLA-A*0301–peptide complex Acta Cryst. (2011). D67, 447–454
Table 1
Crystallization, data collection, phasing, reﬁnement statistics and model quality.
Values in parentheses are for the highest resolution shell.
Crystallization
Protein 6.9 mg ml
 1 in 10 mM HEPES pH 7.0,
10 mM NaCl
Reservoir 20% PEG 3350, 0.1 M Bis-Tris propane pH 8.0,
0.2 M sodium/potassium phosphate (Molecular
Dimensions PACT Premier condition No. 94)
Cryoprotectant 25% ethylene glycol
Data collection
Beamline I04, Diamond Light Source, Oxfordshire, England
Detector ADSC Q315
Software DENZO/SCALEPACK
Space group P212121
Unit-cell parameters (A ˚ ,  ) a = 62.9, b = 65.5, c = 107.3,   =   =   =9 0
Wavelength (A ˚ ) 0.9699
Resolution (A ˚ ) 30.0–2.69 (2.81–2.69)
Completeness (%) 100 (100)
Unique reﬂections 12447 (1223)
Average muliplicity per shell 5.5 (5.7)
hI/ (I)i 7.87 (1.99)
Rmerge† 0.20 (0.94)
Phasing
Method Molecular replacement
Software MOLREP
Model used PDB entry 1duz
Reﬁnement statistics
Software REFMAC5/PHENIX
Resolution (A ˚ ) 20–2.7
Completeness (%) 99.41
No. of unique reﬂections 11859
R factor‡ (%) 19.3
Rfree§ (%) 25.0
R.m.s.d bond length (A ˚ ) 0.006
R.m.s.d. bond angles ( ) 0.981
R.m.s.d. chiral volume (A ˚ 3) 0.067
Average B value for main chains (A ˚ 2) 36.0
Average B value for side chains and waters (A ˚ 2) 40.4
Model quality
Software MolProbity
Total No. of residues 415
Residues in Ramachandran favoured region (%) 96.0
Ramachandran outliers (%) 0.0
PDB code 2xpg
† Rmerge =
P
hkl
P
i jIiðhklÞ h IðhklÞij=
P
hkl
P
i IiðhklÞ, where hkl is the unique reﬂection index, Ii(hkl) is the intensity of
the symmetry-related reﬂection and hI(hkl)i is the mean intensity. ‡ R =
P
hkl
   jFobsj j Fcalcj
   =
P
hkl jFobsj, where hkl
deﬁnes the unique reﬂections. § Rfree was calculated over 5.0% of total reﬂections excluded from reﬁnement.C-terminal binding site (Li & Bouvier, 2004). The canonical
hydrogen-bond network between nonpolymorphic F-pocket
residues and main-chain atoms of the peptide C-terminus is
conserved in A3–PLP45-53 (Guo et al., 1992; Silver et al.,
1992). P9 Lys is further stabilized by a triad of aspartic acid
residues (residues 74, 77 and 116) which serve to anchor the
positively charged peptide side chain within the pocket.
3.2. Comparison of A3–PLP45-53 with other members of the
A3 superfamily
Across the A3-superfamily the architecture of the B pocket
is similar, reﬂecting their overlapping peptide-binding reper-
toires (Sidney et al., 1996). Residues 7, 45, 66, 67 and 99 are
conserved family wide. Residues 63 and 70 are polymorphic,
but Asn (HLA-A33 and HLA-Aw*68) to Glu (HLA-A31,
HLA-A3 and HLA-A11) and Gln (HLA-A3, HLA-A11 and
HLA-Aw*68) to His (HLA-A31 and HLA-A33) substitutions
retain potential hydrogen-bonding forming residues at these
positions. Residue 9, which is known to critically inﬂuence
side-chain preference in the B pocket, is a Phe in HLA-A3. In
the other A3-superfamily members residue 9 is a Tyr and
whilst maintaining the same constraint on the volume of the
pocket, the extra hydrogen-bonding potential may contribute
to the ability of HLA-A11, HLA-A31, HLA-A33 and HLA-
Aw*68 to accommodate a polar Thr side chain as well as more
hydrophobic anchors (Guo et al., 1992; Falk et al., 1994; Kubo
et al., 1994).
Across the A3 superfamily, F-pocket residues 74, 77 and 116
are strictly conserved aspartic acid residues. Consequently,this
negatively charged pocket has a preference for positively
charged Arg and Lys side chains. Notably, however, individual
A3-family submembers exhibit distinct preferences for either
an Arg or a Lys at position 9 (Sidney et al., 1996). Residue 97 is
known to be critical in determining the depth of the F pocket
in HLA-A3-like molecules (Li & Bouvier, 2005) and to
inﬂuence the choice of Arg or Lys at this position. In HLA-A3,
an Ile at position 97 is consistent with the preferred binding of
Lys in the F pocket (Kubo et al., 1994). The branched side
chain of Ile97 narrows the available space in this part of the
groove, favouring accommodation of the Lys side chain rather
than the longer alkyl chain of Arg. Greater space is provided
for the latter to bind by a Met at position 97 in HLA-Aw*68,
HLA-A31 and HLA-A33.
Whilst HLA-A3 is known to confer an enhanced relative
risk of MS, a sister allele of the A3 superfamily, HLA-A11
(A11), has no notable association with MS risk. This differ-
ence in associated risk is striking as HLA-A3 and HLA-A11
differ by only seven residues in the extracellular region of
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Figure 2
Structural comparison of HLA-A11 with HLA-A3 and HLA-Aw*68. (a)
The C
  atoms of residues that differ between HLA-A11 (grey) and HLA-
A3 (red) are represented as small spheres, labelled and coloured cyan if
the side chains point into the binding groove and purple if they do not.
The  1 and  2 helices are as indicated. (b)T h eC
  atoms of residues that
differ between HLA-A11 (grey) and HLA-Aw*68 (green) are repre-
sented as small spheres, labelled and coloured blue if the side chains point
into the binding groove in HLA-A3 and orange if they do not. The  1 and
 2 helices are as indicated.
Table 2
List of atomic interactions between HLA-A3 and proteolipid protein
(PLP) residues 45–53 (KLIETYFSK).
Peptide Hydrogen-bond partner†
Residue Atom Residue Atom Distance
(A ˚ )
Nonbonded contacts‡
Lys (P1) N Tyr171 OH 2.70 Glu63, Trp167
N Tyr7 OH 2.84
O Tyr59 OH 2.59
Leu (P2) N Glu63 OE1 2.77 Tyr7, Met45, Asn66,
Val67
Ile (P3) N Tyr99 OH 3.13 Tyr99, Tyr159
Tyr (P6) OH Asn66 O 2.94 Ala69, Gln70, Thr73
Phe (P7) Trp147, Glu152
Ser (P8) OG Lys146 NZ 3.07
O Trp147 NE1 2.92
Lys (P9) O Tyr84 OH 2.78 Asp77, Tyr123, Tyr147
O Thr143 OG1 3.14
NZ Asp116 (S§) OD2 2.50
N Asp77 OD1 2.87
† The cutoff distance of a hydrogen bond is taken to be 3.2 A ˚ . ‡ Residues involved in
nonbonded contacts were deﬁned as contact residues within 4 A ˚ of any PLP45-53 peptide
atom. § S denotes the existence of a salt bridge.their heavy chain, of which only four residues (9, 152, 156 and
163) inﬂuence the peptide-binding groove (Fig. 2a).
Detailed comparison of the structure of A3–PLP45-53 with
that of HLA-A11 presenting two nonamer peptides from HIV
reverse transcriptase (RT313-321) and SARS nucleocapsid
protein (SNP362–370) [PDB entries 1q94 (Li & Bouvier,
2004) and 1x7q (Blicher et al., 2005), respectively] indicates
that one polymorphic residue, 152 (Fig. 2a), is sufﬁcient to
alter peptide binding between these two MHC class I mole-
cules. Glu152 (A3) and Ala152 (A11) make differing contacts
to the respective P7 residue which correlates with the absence
(A3/PLP45-53) and presence (A11/RT313-321 and A11/
SNP362-370) of a secondary anchor respectively at the adja-
cent P6 residue, inﬂuencing how deeply each peptide binds
within the groove.
As with HLA-A11, HLA-Aw*68, another sister allele of the
A3 superfamily, has no known association with MS. HLA-
Aw*68 differs from HLA-A3 at 16 residues in its heavy chain
and thus at the level of its amino-acid sequence is less similar
to HLA-A3 than HLA-A11. Of the six polymorphic residues
between HLA-A11 and HLA-Aw*68 (Fig. 2b) with the
potential to alter peptide binding (62, 63, 97, 152, 156 and 163),
the most signiﬁcant alterations between the two alleles are
again in the central section of the binding groove. In HLA-
Aw*68, bulkier residues at 97, 152 and 156 (Met, Val and Trp)
make the groove shallower and narrower in the vicinity of the
C and E pockets relative to HLA-A11, where these residues
are Ile, Ala and Glu, respectively. Consequently, HLA-Aw*68
and HLA-A11 may be predicted to bind the same peptides
because of the shared primary anchor preferences, but can be
expected to present them in differing manners. Supporting
this, the nonamer peptides RT313-321 and Nef73-82 both bind
with high afﬁnity to HLA-A11 (and HLA-A3) but bind
considerably more weakly to HLA-Aw*68. Whilst members of
the A3 superfamily can have similar peptide-binding reper-
toires, polymorphic differences can modify the nature and
stability of the MHC–peptide interaction (Li & Bouvier,
2005), which in turn has implications for TCR interactions.
HLA-B2705 and HLA-B2709 (Hu ¨lsmeyer et al., 2002), which
are disease-associated and non-associated for spondyloar-
thropathies, respectively, have previously illustrated the power
of a single amino-acid alteration to modulate disease asso-
ciation of alleles presenting a common peptide. In the case of
the HLA-A3 superfamily, subtle alterations among the
binding grooves of HLA-A3, HLA-A11 and HLA-Aw*68
could potentially have signiﬁcant implications for peptide
presentation of autoantigen peptides such as PLP45-53 and
hence their associated disease risk.
3.3. HLA-A3 and HLA-A2 differ in the architecture of their
binding grooves but present the same HLA surface for TCR
recognition
Superposition of the structure of HLA-A3–PLP45-53 with
the previously reported crystal structure of HLA-A2 (PDB
entry 1duz) indicates that the overall architecture of the HLA-
A3 peptide-binding groove is essentially identical to that of
HLA-A2 (0.5 A ˚ r.m.s.d. for superposition of the 179 equiva-
lent pairs of C
  atoms of the  1 and  2 domains). The position
of the  3 domain relative to the binding groove and  2m is
subject to a small rigid-body shift between HLA-A3 and
HLA-A2, but the individual  3 domains are essentially iden-
tical (0.36 A ˚ r.m.s.d. for superposition of 96 equivalent pairs of
C
  atoms; Fig. 3a). This is consistent with previous compar-
isons of the isolated MHC class I molecules in which the  3
domain was observed to vary in its position relative to the rest
of the molecule by up to 3.5  (Madden, 1995).
The heavy chains of HLA-A3 and HLA-A2 differ by only
19 amino acids (93% shared sequence identity). These poly-
morphic residues map primarily to the binding groove, where
the speciﬁc nature and orientation of the side chain confers a
distinct character on the respective grooves (Table 3, Figs. 3b
and 3c).
HLA-A3 and HLA-A2 exhibit overlapping preferences for
P2 anchors in the B pocket (Val, Leu and Met in HLA-A3;
Leu and Met in HLA-A2; Kubo et al., 1994; Falk et al., 1991;
Table 3). Of the residues contributing to the B pocket, only
position 66 differs between HLA-A3 and HLA-A2 (Asn and
Lys, respectively). This substitution does not affect HLA-A3
binding of P2 Leu, which is positioned under Asn66 pointing
towards the  1 helix (Fig. 3c), nor does it alter the character of
the pocket, which remains predominantly hydrophobic.
The majority of structural differences between the binding
grooves of HLA-A3 and HLA-A2 are within the mid-section
of the groove, arising from polymorphisms at positions 70, 97,
114 and 116 (Figs. 3b and 3c). Ile97 (Arg in HLA-A2)
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Table 3
Peptide-binding groove polymorphisms between HLA-A2 and the A3 superfamily.
Adapted from Kubo et al. (1994).
Residues Residues Residues
B pocket F pocket Central groove
Allele 9 45 63 66 67 70 99 Anchor residue 74 77 80 81 116 Anchor residue 62 73 97 114
HLA-A2 F M E K V H Y L, M (Falk et al., 1991) D D T L Y V (Falk et al., 1991) G T R H
HLA-A3 F M E N V Q Y V, L, M (Kubo et al., 1994) D D T L D K (Kubo et al., 1994) Q T I R
HLA-A11 Y M E N V Q Y T, V (Kubo et al., 1994) D D T L D K (Kubo et al., 1994) Q T I R
HLA-Aw*68 Y M N N V Q Y T, V (Guo et al., 1992) D D T L D R (Guo et al., 1992) R T M R
HLA-A33 T M N N V H Y A, I, L, F, Y, V (Falk et al., 1994) D D T L D R (Falk et al., 1994) R I M Q
HLA-A31 T M E N V H Y L, V, Y, F (Falk et al., 1994) D D T L D R (Falk et al., 1994) Q I M Qgenerates a more open C-pocket in HLA-A3 relative to HLA-
A2, whilst Gln70 (His in HLA-A2) leaves space to accom-
modate the P6 Tyr side chain, which is directed diagonally
towards the  1 helix in A3–PLP45-53. Substitution of Tyr (the
residue in HLA-A2) by Asp at position 116 in HLA-A3 opens
the base of the F pocket, providing a sufﬁcient volume to
accommodate P9 Lys which would be sterically hindered in
HLA-A2. In addition, the F pocket of HLA-A2 is much more
hydrophobic than HLA-A3, reﬂecting its preference for Val at
P9 (Table 3).
Whilst their respective grooves vary markedly, there are
notably no residue differences between HLA-A3 and HLA-
A2 which are directly exposed at the TCR recognition surface
on the  1 and  2 helices (Fig. 3b) Therefore, HLA-A3 and
HLA-A2 present structurally identical surfaces for TCR
engagement. Conversely, the differing internal architecture of
the binding grooves is consistent with
HLA-A3 and HLA-A2 presenting a
divergent pool of peptides. However,
the exposed features of these peptides
could in some cases be similar (as
observed for some peptide–MHC class
II structures; Lang et al., 2002). Thus,
the similarity in surface contribution for
TCR recognition by HLA-A3 and
HLA-A2 suggests the possibility of
structural mimicry occurring between
HLA-A3 peptide and HLA-A2 peptide
complexes, providing the potential to
promote TCR cross-reactivity and to
modify thymic selection.
Among HLA class I alleles, HLA-A2
is the commonest worldwide and its
high frequency in most populations
suggests that it is a particularly impor-
tant player in protective T-cell mediated
immunity. This could reﬂect either the
ability to present (i) a single dominant
epitope from a ubiquitous pathogen, (ii)
some peptide sequence(s) widely
conserved among microbial species or
(iii) some special versatility in its
peptide-presenting abilities, possibly
because of its somewhat indiscriminate
preferences for hydrophobic anchor
residues. Indeed, it presents epitopes
from such globally important pathogens
as inﬂuenza, Epstein–Barr and hepatitis
viruses as well as malaria (Browning &
Krausa, 1996). Possibly, it may also have
been selected in human evolution
because of an ability to inﬂuence the
actions of other MHC molecules and
moderate T-cell responses to pathogens.
Interestingly, the HLA-A2 and HLA-
A3 alleles are derived from two distinct
MHC class I lineages dating back to the
common ancestor of humans, gorillas
and chimpanzees; whereas only one
type has survived in each of the ape
lineages, humans have retained both.
Thus, the HLA-A2 and HLA-A3 alleles
must have co-evolved over millions of
years, allowing many opportunities for
reﬁnement of the beneﬁcial TCR cross-
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Figure 3
Structural comparison of HLA-A3 and HLA-A2. (a) Superposition of A3–PLP45-53 (blue) and
HLA-A2 (orange). HLA-A3 and HLA-A2 show a high degree of equivalence in their  1,  2 and
 2m domains. The  3 domains of HLA-A3 and HLA-A2 are also very structurally similar, but the
relative position of this domain is subject to a rigid-body shift between molecules. (b)T h eC
  atoms
of residues that differ between HLA-A3 and HLA-A2 are represented as small spheres and
coloured cyan if the side chains point into the binding groove in HLA-A3 and dark blue if they do
not. The  1 and  2 helices are labelled. (c) Viewed from above the binding groove, PLP45-53 (grey)
is shown bound to HLA-A3 (blue) and superposed upon the structure of HLA-A2 (orange). The
groove is orientated as in Fig. 3(b). Polymorphic HLA-A3 residues that differ from HLA-A2 and
that contribute to peptide binding are labelled.reactivities which might modulate thymic selection to provide
enhanced protection against autoimmune diseases such as MS
(Lawlor et al., 1991).
4. Concluding remarks
Here, we present the ﬁrst crystal structure of HLA-A3 in
complex with an autoantigenic peptide from a proteolipid
protein which is implicated in MS pathogenesis. Analysis of
the structure of A3–PLP45-53 and comparison with HLA-A2
reveal a potential role for TCR cross-reactivity with HLA-A3
and A2 to modify T-cell selection and TCR expression in vivo
(Friese et al., 2008). Comparison of HLA-A3–PLP45-53 to
other HLA-A3-like molecules suggests that subtle alterations
in the binding groove of HLA-A3-like molecules may sufﬁ-
ciently alter the presentation of a common peptide to explain
different positive and neutral disease associations of HLA-
A3-family members.
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